What Happened
- Commerce and Industry Minister Piyush Goyal stated that India's Free Trade Agreements (FTAs) are opening new export opportunities for the pharmaceutical, healthcare, and medical technology (MedTech) sectors, strengthening India's position in global trade.
- Under the current government, India has signed nine FTAs in the last three to three-and-a-half years, of which five have been concluded in the past 12 months — nearly two-thirds of global trade is now accessible to India under preferential terms.
- The Minister called for building a comprehensive healthcare ecosystem integrating manufacturing, innovation, startups, and hospitals to fully capitalise on FTA-created opportunities.
- He emphasised skilling professionals such as caregivers and nurses for both domestic and international demand, and called for expanding research and standardisation in traditional medicine systems (Ayurveda, Yoga) for global markets.
- MedTech startups were specifically urged to go global, leveraging FTA-enabled lower tariffs and expanded market access.
Static Topic Bridges
India as the "Pharmacy of the World"
India is the world's third largest pharmaceutical producer by volume and the 13th largest by value. It supplies approximately 20% of global generic medicine by volume, 40% of US generic drug demand, and 60% of global vaccine supply by volume — earning the epithet "pharmacy of the world." India has the highest number of US FDA-approved manufacturing plants outside the United States and exports to over 200 countries. The pharmaceutical sector's exports stood at approximately US$ 30.38 billion in FY2024-25.
- India produces over 60,000 generic drugs across 60 therapeutic categories.
- Approximately 70% of pharmaceutical exports go to highly regulated markets (North America, Europe).
- India is the largest vaccine manufacturer globally by volume.
- Key export destinations: US, UK, Germany, South Africa, Russia.
Connection to this news: FTAs targeting pharma-sector tariff reductions in new markets (e.g., UAE CEPA, Australia ECTA) directly amplify India's existing competitive advantage in generics and vaccines, potentially growing the export base beyond current regulated-market concentration.
Free Trade Agreements: Structure and Strategic Use
A Free Trade Agreement (FTA) is a treaty between two or more countries to reduce or eliminate tariff and non-tariff barriers on goods and services traded between them. Comprehensive FTAs also cover investment, intellectual property, services, and government procurement. India's FTA strategy under the current government has shifted from earlier caution to active deal-making, with agreements signed with the UAE (CEPA, 2022), Australia (ECTA, 2022), UK (under finalisation), GCC, and others. Preferential access — lower import duties for Indian goods in partner countries — is the core commercial benefit.
- FTA = Free Trade Agreement; CEPA = Comprehensive Economic Partnership Agreement (broader scope).
- India-UAE CEPA (2022): India's first CEPA in a decade; pharmaceuticals received zero-duty access.
- India-Australia ECTA (2022): Reduced tariffs on pharma, textiles, jewellery.
- Nine FTAs signed in ~3.5 years as of March 2026 — unprecedented pace for India.
- Two-thirds of global trade now accessible to India under preferential terms.
Connection to this news: The minister's statement signals a deliberate policy push to use FTA-negotiated preferential tariffs as a lever to drive pharma and MedTech exports — translating geopolitical deal-making into sectoral commercial gains.
India's MedTech Sector: Scale and Growth Potential
India's MedTech sector — encompassing medical devices, diagnostics, and healthcare technology — is valued at approximately US$ 12 billion and is the fourth largest in Asia. It is growing at 15% annually but remains import-dependent (70-75% of medical devices are imported). The government has introduced Production Linked Incentive (PLI) schemes for medical devices to boost domestic manufacturing. FTAs with tariff concessions in partner markets can convert India's low-cost manufacturing advantage into a significant export opportunity.
- India MedTech market: ~US$ 12 billion, 4th largest in Asia.
- Import dependence: ~70-75% of devices imported (mainly from US, Germany, Japan).
- PLI scheme for medical devices: approved outlay of ₹3,420 crore.
- Key MedTech categories: imaging equipment, consumables, diagnostics, surgical instruments.
- India's comparative advantage: cost-competitive manufacturing, IT integration, English-language professionals.
Connection to this news: FTAs open partner-country markets to Indian MedTech producers at lower tariffs, while the minister's call for an integrated healthcare ecosystem addresses the domestic supply-side gap needed to scale exports.
Key Facts & Data
- Nine FTAs signed by India in ~3.5 years; five concluded in the past 12 months.
- India: 3rd largest pharma producer by volume, 13th by value globally.
- Pharmaceutical exports: ~US$ 30.38 billion in FY2024-25.
- India supplies 20% of global generic medicines and 60% of global vaccines by volume.
- 40% of US generic drug demand met by India.
- India has the highest number of US FDA-approved plants outside the USA.
- MedTech sector: ~US$ 12 billion, 4th largest in Asia, growing at ~15% p.a.
- Two-thirds of global trade now open to India under preferential FTA terms.
- UAE CEPA (2022) granted Indian pharma zero-duty access.